JP2014523250A5 - - Google Patents

Download PDF

Info

Publication number
JP2014523250A5
JP2014523250A5 JP2014520310A JP2014520310A JP2014523250A5 JP 2014523250 A5 JP2014523250 A5 JP 2014523250A5 JP 2014520310 A JP2014520310 A JP 2014520310A JP 2014520310 A JP2014520310 A JP 2014520310A JP 2014523250 A5 JP2014523250 A5 JP 2014523250A5
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
polypeptide
pharmaceutical composition
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014520310A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523250A (ja
JP6110377B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/046422 external-priority patent/WO2013055420A2/en
Publication of JP2014523250A publication Critical patent/JP2014523250A/ja
Publication of JP2014523250A5 publication Critical patent/JP2014523250A5/ja
Application granted granted Critical
Publication of JP6110377B2 publication Critical patent/JP6110377B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014520310A 2011-07-12 2012-07-12 新規クロストリジウム・ディフィシル(Clostridiumdifficile)DNAワクチン Expired - Fee Related JP6110377B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161506973P 2011-07-12 2011-07-12
US61/506,973 2011-07-12
PCT/US2012/046422 WO2013055420A2 (en) 2011-07-12 2012-07-12 Novel clostridium difficile dna vaccine

Publications (3)

Publication Number Publication Date
JP2014523250A JP2014523250A (ja) 2014-09-11
JP2014523250A5 true JP2014523250A5 (enExample) 2015-08-27
JP6110377B2 JP6110377B2 (ja) 2017-04-05

Family

ID=48082709

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014520310A Expired - Fee Related JP6110377B2 (ja) 2011-07-12 2012-07-12 新規クロストリジウム・ディフィシル(Clostridiumdifficile)DNAワクチン

Country Status (8)

Country Link
US (1) US9446112B2 (enExample)
EP (1) EP2741785B1 (enExample)
JP (1) JP6110377B2 (enExample)
KR (1) KR101955365B1 (enExample)
CN (1) CN104203287B (enExample)
AU (1) AU2012321317B2 (enExample)
CA (1) CA2846486C (enExample)
WO (1) WO2013055420A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0629101B2 (ja) 1987-05-29 1994-04-20 株式会社片岡機械製作所 シ−トロ−ル取外し装置付きシ−ト分割巻取機
JP2981606B2 (ja) 1997-11-19 1999-11-22 株式会社不二鉄工所 スリット装置における多軸巻取装置
WO2014197651A1 (en) * 2013-06-05 2014-12-11 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
WO2025129186A1 (en) * 2023-12-14 2025-06-19 The Trustees Of The University Of Pennsylvania Clostridioides difficile vaccine and methods of use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186194A (en) 1973-10-23 1980-01-29 Agence Nationale De Valorisation De La Recherche (Anvar) Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
US4082735A (en) 1976-04-26 1978-04-04 Syntex (U.S.A.) Inc. Novel immunological adjuvant compounds and methods of preparation thereof
US4082736A (en) 1976-04-26 1978-04-04 Syntex (U.S.A.) Inc. Novel immunological adjuvant compounds and methods of preparation thereof
GB1563561A (en) 1976-06-23 1980-03-26 Daiichi Seiyaku Co Muramyldipeptide derivatives and process for the preparation thereof
FR2368282A1 (fr) 1976-10-22 1978-05-19 Anvar Adjuvant immunologique constitue par le p-amino-phenyl de n-acetyl-muramyl-l-alanyl-d-isoglutamine
FI75578C (fi) 1979-07-25 1988-07-11 Ciba Geigy Ag Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider.
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
EP0752885B1 (en) 1992-09-25 2003-07-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
CA2401327C (en) 2000-03-03 2014-05-06 Valentis, Inc. Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
CA2424216A1 (en) 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US20040014645A1 (en) 2002-05-28 2004-01-22 Advisys, Inc. Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US20050070841A1 (en) 2002-07-04 2005-03-31 Inovio As Electroporation device and injection apparatus
DK1766093T3 (da) * 2004-02-06 2011-10-03 Univ Massachusetts Antistoffer mod clostridium difficile-toksiner og anvendelse deraf
KR20080086983A (ko) 2005-12-07 2008-09-29 제네트로닉스, 인코포레이티드 가변 부피의 전기천공 챔버 및 이의 사용 방법
WO2007146139A2 (en) * 2006-06-08 2007-12-21 Cornell Research Foundation, Inc. Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b
WO2011060431A2 (en) * 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease

Similar Documents

Publication Publication Date Title
HRP20190799T1 (hr) Imunocitokini na bazi il-15 i sushi domene il-15r alfa
RU2012153218A (ru) Пептиды, проникающие в клетки, и их применения
WO2014018858A3 (en) Multimeric fusion protein vaccine and immunotherapeutic
BR112013032723A2 (pt) antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
JP2012501959A5 (enExample)
JP2011136997A5 (enExample)
JP2018528237A5 (enExample)
FI3378535T3 (fi) Alfa-synukleiinin tunnistavia humanisoituja vasta-aineita
RU2015122368A (ru) Слитые белки для применения в качестве иммуногенных усиливающих агентов для индуцирования антигенспецифического т-клеточного ответа
JP2012126742A5 (enExample)
JP2016539946A5 (enExample)
JP2011530309A5 (enExample)
MX2018009225A (es) Inmunoterapia basada en vectores de distribución personalizados y usos de la misma.
JP2014510519A5 (enExample)
RU2015135890A (ru) Композиция вакцины
BR112012008946A2 (pt) sequência polinucletídica isolada , molécula pollinucleotídica de rna, vetor ou plasmídeo , célula hospedeira , vírus a ser expresso , vacina , polipetídeo e composição de vacina
JP2015524422A5 (enExample)
JP2015500827A5 (enExample)
JP2014523250A5 (enExample)
JP2014529399A5 (enExample)
MX2011007307A (es) Vector de expresion estable contitutivamente alto para preparar vacuna vph y bacteria acido lactica recombinante transformada del mismo modo.
RU2015140603A (ru) Вакцины на основе нуклеопротеина вируса гриппа
CN102993308B (zh) 耐甲氧西林金黄色葡萄球菌(mrsa)疫苗重组蛋白抗原hi2及制备方法和应用
JP2017538443A5 (enExample)